The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.

Advanced non-small cell lung cancer (NSCLC) patients harboring mutations in the EGFR gene show good responses to first, second and third generation tyrosine kinase inhibitors (TKIs) but ultimately relapse.